Call 1-888-222-8475

Home

This site is intended only for residents of the United States and Puerto Rico.

SITE MAP

  • Home
  • For Healthcare Providers
    • Access & Reimbursement
    • Affordability & Other Support
  • For Patients
  • PFIZER.COM
  • TERMS OF USE
  • PRIVACY POLICY
  • SITE MAP
 

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088.

VyndaLink offerings are available to residents of the United States and Puerto Rico only. The product information provided in this site is intended only for residents of the United States and Puerto Rico. The products discussed may have different product labeling in different countries.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

© 2019 Pfizer Inc. All rights reserved.

PP-VYN-USA-0096 May 2019

Interim Care Program Terms and Conditions

  • Interim Care is not health insurance and is only available for eligible patients who are insured through a commercial or federal insurance program.
  • Offer is only available for patients new to therapy (excluding any participation in a clinical trial) who have a valid prescription and an on-label diagnosis for VYNDAQEL (tafamidis meglumine).
  • Interim Care is only for new patients who have experienced a delay in coverage determination of at least 5 business days after our receipt of the patient's prescription.
  • Patients who qualify for co-payment assistance from another Pfizer patient assistance program are ineligible.
  • Neither the patient, nor the pharmacy or anyone else acting on the patient’s behalf, may submit any claim for reimbursement for product dispensed pursuant to this Interim Care program to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. Out-of-pocket expenses incurred when using this program cannot be applied toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP).
  • If the patient is enrolled in a Medicare Part D plan, they must provide the address of their plan in order to be eligible for the Interim Care program.
  • Available in 30-day supply. Refills are subject to limitations.
    • To be eligible for an additional 30-day refill, the patient must be actively pursuing coverage through their insurance awaiting a prior authorization/appeal decision. Interim Care for VYNDAQEL may not exceed 60 days for any patient.
  • Interim Care offer does not require, nor will be made contingent on, purchase requirements of any kind.
  • Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification.
  • Interim Care can only be dispensed by the exclusive pharmacy and only after benefits investigation has been completed and a delay has occurred in the prior authorization or appeals process.
  • Offer good only in the US and Puerto Rico.
  • Prescription must be provided by a healthcare provider licensed in the US or Puerto Rico.
  • Additional eligibility criteria may apply. Contact VyndaLink for details.

External link popup

you are now leaving the vyndalink website

Links to other websites are provided as a convenience to you.

Pfizer accepts no responsibility for the content of linked sites.

continue

vyndalink portal coming soon